Analysts expect Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) to post earnings of ($0.26) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Aevi Genomic Medicine’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.32). Aevi Genomic Medicine posted earnings of ($0.35) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 25.7%. The business is expected to report its next quarterly earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Aevi Genomic Medicine will report full year earnings of ($1.10) per share for the current fiscal year, with EPS estimates ranging from ($1.29) to ($0.88). For the next financial year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.85) to ($1.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Aevi Genomic Medicine.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.02.

Several research firms have recently weighed in on GNMX. Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price (down from $12.00) on shares of Aevi Genomic Medicine in a report on Tuesday, March 21st. Jefferies Group LLC downgraded Aevi Genomic Medicine from a “buy” rating to a “hold” rating and reduced their target price for the company from $10.00 to $2.50 in a report on Tuesday, March 21st. Finally, ValuEngine downgraded Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

TRADEMARK VIOLATION WARNING: “Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Expected to Announce Earnings of -$0.26 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/07/aevi-genomic-medicine-inc-nasdaqgnmx-expected-to-announce-earnings-of-0-26-per-share.html.

Shares of Aevi Genomic Medicine (GNMX) traded down 1.50% on Friday, hitting $1.31. The stock had a trading volume of 238,034 shares. The company’s market cap is $48.61 million. The stock has a 50 day moving average price of $1.28 and a 200-day moving average price of $3.31. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $17.75.

In related news, Director Sol J. Barer purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $154,000.00. Following the transaction, the director now directly owns 507,000 shares of the company’s stock, valued at approximately $780,780. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 46,149 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 13,966 shares during the period. Birchview Capital LP boosted its position in shares of Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 20,000 shares during the period. Finally, Teachers Advisors LLC bought a new position in shares of Aevi Genomic Medicine during the fourth quarter valued at about $204,000. Hedge funds and other institutional investors own 27.87% of the company’s stock.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.